Due to the efficacy, safety and tolerability of the CDK4/6 inhibitors in HR+ breast cancer, and multiple nodes of oncogenic signals converging on CDK4/6 in multiple cancer types [16], there has been significant interest in extending their use to other cancer types. This evidence concerns the gene CDK4 and breast carcinoma.